Nivolumab + cabozantinib (RCC, 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-NIVOLUMAB` `DRUG-CABOZANTINIB`

ID	`REG-NIVO-CABO-RCC`
Type	Regimen
Status	reviewed 2026-05-03 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-CHECKMATE-9ER-CHOUEIRI-2021` `SRC-ESMO-RCC-2024` `SRC-NCCN-KIDNEY-2025`

Notes

CheckMate-9ER: nivo+cabo vs sunitinib, PFS 16.6 vs 8.3 mo (HR 0.51), mOS 37.7 vs 34.3 mo (HR 0.70), ORR 55.7% vs 27.1%. Cabo dose 40 mg (not 60 mg monotherapy dose) in combination. Benefit across all IMDC risk groups. Tolerable safety profile relative to other ICI+TKI combos; preferred when MET pathway co-activation is suspected or in papillary histology (off-label, but biological rationale via MET). Max nivolumab duration 2 years; cabozantinib continues until progression.

Used By

Indication

IND-HCC-SYSTEMIC-2L-CABOZANTINIB - IND-HCC-SYSTEMIC-2L-CABOZANTINIB
IND-RCC-METASTATIC-1L-NIVO-CABO - IND-RCC-METASTATIC-1L-NIVO-CABO

Regimen

REG-CABOZANTINIB-HCC - Cabozantinib (HCC, 2L)
REG-CABOZANTINIB-RCC - Cabozantinib monotherapy (RCC, 2L)